{"wiki_id": "http://www.wikidata.org/entity/Q51549687", "itemLabel": "Michael J. Reed", "itemDescription": "British biochemist", "wikipedia_url": "https://en.wikipedia.org/wiki/Michael_J._Reed", "wikipedia_page": {"main": "Professor Michael J. Reed  (30 May 1944 \u2013 6 April 2009) was a British chemist who held the position of professor of steroid biochemistry at Imperial College, London.", "link_mentions": [{"page": "Michael Reed", "response": ["*Michael J. Reed (1944\u20132009), British chemist"]}, {"page": "Irosustat", "response": ["Irosustat (, ; developmental code names STX-64, 667-coumate, BN-83495; also known as oristusane) is an orally active, irreversible, nonsteroidal inhibitor of steroid sulfatase (STS) and member of the aryl sulfamate  ester class of drugs that was under development by Sterix Ltd and  Ipsen for the treatment of hormone-sensitive cancers such as breast cancer, prostate cancer, and endometrial cancer but has not yet been marketed. The drug was first designed and synthesized in the group of Professor Barry V L Potter at the Department of Pharmacy & Pharmacology, University of Bath,  working together with Professor Michael J. Reed at Imperial College, London and its initial development was undertaken through the university spin-out company Sterix Ltd and overseen by Cancer Research UK (CRUK). Results of the \"first-in-class\" clinical trial in breast cancer of an STS inhibitor in humans were published in 2006 and dose optimisation studies and further clinical data have been reported."]}]}}